Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
AHA Scientific Sessions 2026 | New warnings for GLP-1 drugs | TAVR for moderate AS | $455M to develop a next-gen heart pump
Tuesday, November 10, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

AHA Scientific Sessions 2026: Key trends include AI, negative trial results and multidisciplinary care

Meeting chair Joanna Chikwe, MD, spoke to Cardiovascular Business about some of her biggest takeaways from the four-day event.

READ MORE >
Video interview with Joanna Chikwe, MD, FRCS, chair on the American Heart Association 2026 Scientific Sessions, and chair of the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai, explains some key trends in cardiology at the AHA meeting. #AHA2026
Share on Twitter Share on Facebook Share on Linkedin

AHA Scientific Sessions 2026: Key trends include AI, negative trial results and multidisciplinary care

Share on Twitter Share on Facebook Share on Linkedin
Video interview with Joanna Chikwe, MD, FRCS, chair on the American Heart Association 2026 Scientific Sessions, and chair of the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai, explains some key trends in cardiology at the AHA meeting. #AHA2026
Meeting chair Joanna Chikwe, MD, spoke to Cardiovascular Business about some of her biggest takeaways from the four-day event.
READ MORE >

FDA requires new safety warnings for GLP-1 drugs

The FDA is now requiring labeling updates for all GLP-1 medications due to a risk of NAION, a rare eye condition that can result in sudden, permanent vision loss.

READ MORE >
obesity semaglutide tirzepatide GLP-1 drugs weight loss
Share on Twitter Share on Facebook Share on Linkedin

FDA requires new safety warnings for GLP-1 drugs

Share on Twitter Share on Facebook Share on Linkedin
obesity semaglutide tirzepatide GLP-1 drugs weight loss
The FDA is now requiring labeling updates for all GLP-1 medications due to a risk of NAION, a rare eye condition that can result in sudden, permanent vision loss.
READ MORE >

Medtronic studying safety, effectiveness of its self-expanding TAVR valves in patients with moderate AS

This represents the first randomized trial focused on treating moderate aortic stenosis with Medtronic's self-expanding, supra-annular Evolut platform. 

READ MORE >
Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The larger coronary access window in the frame of the Evolut FX+. Image courtesy of Medtronic.
Share on Twitter Share on Facebook Share on Linkedin

Medtronic studying safety, effectiveness of its self-expanding TAVR valves in patients with moderate AS

Share on Twitter Share on Facebook Share on Linkedin
Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The larger coronary access window in the frame of the Evolut FX+. Image courtesy of Medtronic.
This represents the first randomized trial focused on treating moderate aortic stenosis with Medtronic's self-expanding, supra-annular Evolut platform. 
READ MORE >

Boston Scientific inks $455M deal with global investment firm to work on next-gen heart pump

The device in question is a microaxial heart pump for the treatment of acute myocardial infarction-related cardiogenic shock.

READ MORE >
American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.
Share on Twitter Share on Facebook Share on Linkedin

Boston Scientific inks $455M deal with global investment firm to work on next-gen heart pump

Share on Twitter Share on Facebook Share on Linkedin
American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.
The device in question is a microaxial heart pump for the treatment of acute myocardial infarction-related cardiogenic shock.
READ MORE >

Featured Articles

NCD and the dawn of a new era: What expanded TAVR coverage means for patient care

Sponsored by Edwards Lifesciences

Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.

READ MORE >
Doctors comforting disabled elderly patient
Share on Twitter Share on Facebook Share on Linkedin

NCD and the dawn of a new era: What expanded TAVR coverage means for patient care

Sponsored by Edwards Lifesciences

Share on Twitter Share on Facebook Share on Linkedin
Doctors comforting disabled elderly patient
Curtiss Stinis, MD, has been performing TAVR for nearly two decades. He says the new policies from CMS that expand coverage for asymptomatic patients represent a "momentous step forward" for heart patients with severe aortic stenosis.
READ MORE >

Evolocumab prevents more heart attacks than ezetimibe in head-to-head comparison

The monoclonal antibody drug was associated with a 20% lower rate of fatal and nonfatal myocardial infarction over four years. 

READ MORE >
Evolocumab limits adverse cardiovascular outcomes among PCI patients
Share on Twitter Share on Facebook Share on Linkedin

Evolocumab prevents more heart attacks than ezetimibe in head-to-head comparison

Share on Twitter Share on Facebook Share on Linkedin
Evolocumab limits adverse cardiovascular outcomes among PCI patients
The monoclonal antibody drug was associated with a 20% lower rate of fatal and nonfatal myocardial infarction over four years. 
READ MORE >

SCAI refines cardiogenic shock classifications

The update is seen as an important step toward unifying the field around a common framework while identifying areas where more evidence is needed.

READ MORE >
Srihari Naidu, MD, FACC, FAHA, MSCAI, Immediate-Past SCAI President, Director, Cath Labs, Westchester Medical Center, explained the new 2026 SCAI SHOCK Classification Expert Consensus Update.
Share on Twitter Share on Facebook Share on Linkedin

SCAI refines cardiogenic shock classifications

Share on Twitter Share on Facebook Share on Linkedin
Srihari Naidu, MD, FACC, FAHA, MSCAI, Immediate-Past SCAI President, Director, Cath Labs, Westchester Medical Center, explained the new 2026 SCAI SHOCK Classification Expert Consensus Update.
The update is seen as an important step toward unifying the field around a common framework while identifying areas where more evidence is needed.
READ MORE >

GE HealthCare investment in AI-powered TEE robotics part of growing automation trend

The Laza robotic TEE imaging system combines real-time 3D heart modeling, procedural guidance, robotic probe control and an intuitive interface. 

READ MORE >
The Laza Medical autonomous TEE robotic system invested in by GE Healthcare.
Share on Twitter Share on Facebook Share on Linkedin

GE HealthCare investment in AI-powered TEE robotics part of growing automation trend

Share on Twitter Share on Facebook Share on Linkedin
The Laza Medical autonomous TEE robotic system invested in by GE Healthcare.
The Laza robotic TEE imaging system combines real-time 3D heart modeling, procedural guidance, robotic probe control and an intuitive interface. 
READ MORE >

In Case You Missed It

Surgeon highlights the historical significance of new adjustable heart valve for children

A new FDA-approved pulmonary valve should reduce the number of open-heart surgeries children with congenital heart disease require as they grow older. Emile Bacha, MD, explained the importance of this device in a new video interview. 

READ MORE >
Emile Bacha, MD, chair, Department of Surgery, surgeon-in-chief at NewYork-Presbyterian Hospital / Columbia University Medical Center, and past president of the American Association for Thoracic Surgery (AATS), was a lead investigator in the clinical trial that led to the recent U.S. FDA approval for the Edwards Lifesciences Autus size-adjustable pulmonary valve.
Share on Twitter Share on Facebook Share on Linkedin

Surgeon highlights the historical significance of new adjustable heart valve for children

Share on Twitter Share on Facebook Share on Linkedin
Emile Bacha, MD, chair, Department of Surgery, surgeon-in-chief at NewYork-Presbyterian Hospital / Columbia University Medical Center, and past president of the American Association for Thoracic Surgery (AATS), was a lead investigator in the clinical trial that led to the recent U.S. FDA approval for the Edwards Lifesciences Autus size-adjustable pulmonary valve.
A new FDA-approved pulmonary valve should reduce the number of open-heart surgeries children with congenital heart disease require as they grow older. Emile Bacha, MD, explained the importance of this device in a new video interview. 
READ MORE >

Heart surgeons now earn more than $1 million per year

Cardiac surgeon compensation is up 11%, according to new survey data from MedAxiom and the American College of Cardiology. Vascular surgeons experienced an increase in pay as well, but it was much smaller.

READ MORE >
Money dollar investments
Share on Twitter Share on Facebook Share on Linkedin

Heart surgeons now earn more than $1 million per year

Share on Twitter Share on Facebook Share on Linkedin
Money dollar investments
Cardiac surgeon compensation is up 11%, according to new survey data from MedAxiom and the American College of Cardiology. Vascular surgeons experienced an increase in pay as well, but it was much smaller.
READ MORE >

Clinicians from all specialties use AI to answer cardiology questions

Overall, more than 950,000 clinicians submitted queries to a popular AI platform from January 2024 to June 2026. Cardiovascular care was a common topic, especially questions about specific treatments and medications. 

READ MORE >
AI healthcare doctor surgery procedure artificial intelligence
Share on Twitter Share on Facebook Share on Linkedin

Clinicians from all specialties use AI to answer cardiology questions

Share on Twitter Share on Facebook Share on Linkedin
AI healthcare doctor surgery procedure artificial intelligence
Overall, more than 950,000 clinicians submitted queries to a popular AI platform from January 2024 to June 2026. Cardiovascular care was a common topic, especially questions about specific treatments and medications. 
READ MORE >

In Other News

Two more indicted in $51M ‘free cellphone’ Medicare fraud conspiracy

The scheme, which has resulted in two guilty pleas to date, allegedly involved the promise of “free cellphones” as a pretense to get Medicare insurance information from patients, which was then used to bill government programs for unnecessary HIV drugs.

READ MORE >
ai artificial intelligence in healthcare
Share on Twitter Share on Facebook Share on Linkedin

Two more indicted in $51M ‘free cellphone’ Medicare fraud conspiracy

Share on Twitter Share on Facebook Share on Linkedin
ai artificial intelligence in healthcare
The scheme, which has resulted in two guilty pleas to date, allegedly involved the promise of “free cellphones” as a pretense to get Medicare insurance information from patients, which was then used to bill government programs for unnecessary HIV drugs.
READ MORE >

Survey identifies gaps in patient instructions for PSMA radiopharmaceutical therapy

These differences could leave patients receiving the same treatment with substantially different instructions depending on where care was delivered. 

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Survey identifies gaps in patient instructions for PSMA radiopharmaceutical therapy

Share on Twitter Share on Facebook Share on Linkedin
These differences could leave patients receiving the same treatment with substantially different instructions depending on where care was delivered. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup